KDR and glioblastoma: Glioma treatment with bevacizumab, an inhibitor of VEGF receptor (VEGFR) expressed on vascular endothelium, has led to increased PFS but no OS benefit in the patients with recurrent GBM and was approved for GBM therapy in 2009 (98).